면역 체크포인트 저해제 시장 - 업계 동향과 세계 예측(-2030년) - 주요 면역 체크포인트 표적별, 대상 적응증별, 작용기서별, 사용되는 치료 모달리티별, 치료법별, 주요 지역별

Immune Checkpoint Inhibitors Market: Overview

As per Roots Analysis, the immune checkpoint inhibitors market is estimated to be worth USD 62 billion in 2025 and reach USD 246 billion in 2035, growing at a CAGR of 14.7% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Immune Checkpoint Inhibitors Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Immune Checkpoint Proteins

• PD-1
• PD-L1
• CTLA-4
• Others

Target Disease Indication

• Lung Cancer
• Breast Cancer
• Bladder Cancer
• Cervical Cancer
• Colorectal Cancer
• Melanoma
• Hodgkin Lymphoma
• Others

Type of Therapeutic Modality

• Antibody Fragments
• Monoclonal Antibodies
• Small Molecules
• Other Modalities

Route of Administration

• Intravenous
• Subcutaneous
• Intracellular
• Others

Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East & Africa
• Latin America

Immune Checkpoint Inhibitors Market: Growth and Trends

Cancer is recognized as a major cause of mortality globally, responsible for 0.6 million fatalities in 2019, in the US alone. The World Health Organization projects that the global incidence of new cancer cases will increase by 70% in the next 20 years. Traditional treatment methods, including chemotherapy, surgical procedures, and radiation therapy, remain the established standard of care. Nonetheless, their effectiveness is significantly constrained, particularly in the treatment of advanced-stage cancers. Further, the non-specific and extremely toxic characteristics of chemotherapy and radiation therapy are recognized to considerably affect the quality of life of individuals.

Numerous targeted cancer treatments are currently available in the market, in addition to the therapies under development. Among these, immune checkpoint therapies have demonstrated significant potential as effective and powerful treatment alternatives, capable of hindering tumor cells from escaping immune detection. In 2011, Yervoy(R) (ipilimumab), an anti-CTLA-4 monoclonal antibody from Bristol-Myers Squibb, was the first immune checkpoint inhibitor approved by the FDA for treating metastatic melanoma. Yervoy(R), together with other early immune checkpoint inhibitors (focusing on PD-1/PD-L1 and CTLA-4), demonstrated potential to significantly extend the lives of individuals with advanced tumors. Nonetheless, despite the effectiveness of PD 1 / PD-L1 immune checkpoint inhibitors, a significant level of resistance to treatment was observed in some patient groups, which hindered the therapeutic effectiveness of this relatively new category of treatments.

Throughout the years, considerable advancements have happened in immune checkpoint modulation research, uncovering various inhibitory (LAG-3, TIM-3, TIGIT, VISTA, and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB, and CD40) that are currently being utilized for the creation of next-generation immune checkpoint-focused therapies. Additionally, clinical research on combinatorial immune checkpoint blockade and co-stimulation, which includes both newly discovered checkpoints and established immune checkpoint inhibitor therapies, has shown the ability to enhance therapeutic advantages. It is important to note that these molecules have also demonstrated the ability to regulate immune tolerance and to prevent or treat autoimmune diseases. Consequently, supported by encouraging clinical outcomes and increasing applicability of therapies under late-stage investigation, the immune checkpoint inhibitors and stimulators market is expected to experience significant growth throughout the forecast period.

Immune checkpoint Inhibitors Market: Key Insights

The report delves into the current state of global immune checkpoint inhibitors market and identifies potential growth opportunities within industry. Some key findings from the report include:

• The success of any clinical research study is heavily dependent on its endpoints and outcome measures used, which should be well defined and reliable, readily measurable, sensitive, and clinically meaningful.
• Since 2000, over 3,600 clinical trials focused on the evaluation of PD-1 / PD-L1 targeting immune checkpoint inhibitors have been registered across the world.
• Presently, there are over 450 scientific articles showcasing the results of completed and ongoing clinical studies; most of these publications are featured in peer-reviewed journals having impact factors ranging from 1 to 20.
• The report features detailed summaries of the key takeaways from 85+ clinical research publications, which showcase and discuss the results of both approved and under development PD-1 / PD-L1 targeting drugs.

• Phase I trials captured in the report feature a variety of new molecular entities designed for PD-1 signaling blockade for the treatment of various types of tumors, including metastatic cancers.
• Phase II trials are primarily focused on how safe a treatment is and how well it works; typically, these studies are conducted for specific indications and may involve combinations of drugs / therapies.
• Phase III of clinical research is an elaborate, multicenter study, involving patients shortlisted based on established selection criteria from across the world; understanding the side effects profile is a key objective.

• The importance of trial design is paramount; it not only serves to optimize, and economize the process, but also helps define critical objectives (such as superiority, non-inferiority, or equivalence) directing the course of research.
• In the contemporary clinical research scenario, multiple new PD-1 / PD-L1 inhibitors are being evaluated, and several of the approved products are also being investigated in combination with other product classes.
• Considering the target-specific nature of these therapies, the expression of PD-L1 is considered an important criterion while designing trials of immune checkpoint blockade-directed treatment options.
• A number of trials have been designed to objectively determine whether the new therapeutic agent, or combination regimen, has sufficient biological activity in order to warrant further research.
• The focus of late phase clinical studies is usually on assessing long term therapy related outcomes and affiliated toxicities, across different groups of patients.
• Although multiple PD-1 / PD-L1 targeting drugs are already in the market, several new biological drug candidates are under evaluation and are likely to enter the market in the foreseen future.

Example Players in the Immune Checkpoint Inhibitors Market

• Bristol-Myers Squibb
• GlaxoSmithKline
• Incyte
• Novartis
• Trillium Therapeutics

Immune Checkpoint Inhibitors Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global immune checkpoint inhibitors market, focusing on key market segments, including [A] key immune checkpoint targets, [B] target indication, [C] mechanism of action, [D] therapeutic modalities used, [H] type of therapy, [I] route of administration, and [J] key geographical regions
• Market Landscape: A comprehensive evaluation of marketed / pipeline molecules, considering various parameters, such as [A] phase of development of lead candidates, [B] target immune checkpoints, [C] mechanism of action, [D] type of therapeutic modality used, [E] route of administration and [F] target disease indication, [G] target therapeutic area and [H] type of therapy.
• Company Profiles: In-depth profiles of next generation immune checkpoint modulators, focusing on [A] company overview, [B] financial information (if available), [C] product portfolio, and [E] recent developments and an informed future outlook.
• Grants Analysis: An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, based on parameters, such as [A] year of grant award, [B] amount awarded, [C] administration institute center, [D] funding institute center, [E] support period, [F] type of grant application, [G] purpose of grant award, [H] grant mechanism, [I] popular target immune checkpoints, [J] responsible study section, [K] focus area, [L] prominent program officers, and [M] type of recipient organizations.
• Partnerships and Collaborations: A comprehensive analysis of various collaborations and partnerships that have been inked amongst stakeholders in this domain, based on [A] year of partnership, [B] type of partnership and [C] regional activity.
• Target Competitiveness Analysis: A detailed analysis of the biological targets, taking into consideration the number of lead molecules based on a particular target, [A] phase of development of candidate therapies, [B] number of grants and [C] number of publications, a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
• Big Pharma Players: A detailed analysis of the big pharma players, based on parameters, such as [A] number of therapies under development, [B] target disease indications, [C] partnership activity, and [D] target portfolio.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
• 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Introduction to Cancer Immunotherapy
• 3.3. Fundamentals of Cancer Immunotherapy
• 3.4. Immune Checkpoint Modulators
• 3.5. First Generation Immune Checkpoint Modulators
• 3.6. Next Generation Immune Checkpoint Modulators
  • 3.6.1. Types of Next Generation Immune Checkpoint Modulators
• 3.7. Challenges-related to Immune Checkpoint Modulation-based Therapy
• 3.8. Future Perspectives

4. CURRENT MARKET LANDSCAPE: MARKETED AND DEVELOPMENT PIPELINE

• 4.1. Chapter Overview
• 4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
• 4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
  • 4.3.1. Analysis by Phase of Development
  • 4.3.2. Analysis by Target Immune Checkpoint
  • 4.3.3. Analysis by Mechanism of Action
  • 4.3.4. Analysis by Therapeutic Modality
  • 4.3.5. Analysis by Route of Administration
  • 4.3.6. Analysis by Target Disease Indication
  • 4.3.7. Analysis by Therapeutic Area
  • 4.3.8. Analysis by Popular Oncological Indication(s) and Popular Target Immune Checkpoint
  • 4.3.9. Analysis by Popular Non-Oncological Indication(s) and Popular Target Immune Checkpoint
  • 4.3.10. Analysis by Popular Disease Indication(s) and Popular Target Immune Checkpoint in Highest Phase of Development
• 4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
  • 4.4.1. Analysis by Year of Establishment
  • 4.4.2. Analysis by Company Size and Geographical Location
  • 4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies
  • 4.4.4. Popular Targets: Distribution by Number of Developers
  • 4.4.5 World Map Representation: Analysis by Geography

5. MARKET LANDSCAPE: THERAPIES TARGETING CD47

• 5.1. Chapter Overview
• 5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies
• 5.3. Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies
  • 5.3.1. Analysis by Phase of Development
  • 5.3.2. Analysis by Therapeutic Modality
  • 5.3.3. Analysis by Route of Administration
  • 5.3.4. Analysis by Target Disease Indication
• 5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies
  • 5.4.1. Analysis by Year of Establishment
  • 5.4.2. Analysis by Company Size and Geographical Location
  • 5.4.3. Leading Developers: Analysis by Number of Therapies
  • 5.4.4. World Map Representation: Analysis by Geography

6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB

• 6.1. Chapter Overview
• 6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies
• 6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies
  • 6.3.1. Analysis by Phase of Development
  • 6.3.2. Analysis by Therapeutic Modality
  • 6.3.3. Analysis by Route of Administration
  • 6.3.4. Analysis by Target Disease Indication
• 6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies
  • 6.4.1. Analysis by Year of Establishment
  • 6.4.2. Analysis by Company Size and Geographical Location
  • 6.4.3. Leading Developers: Analysis by Number of Therapies
  • 6.4.4. World Map Representation: Analysis by Geography

7. CLINICAL TRIAL ANALYSIS

• 7.1. Chapter Overview
• 7.2. Scope and Methodology
• 7.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis
  • 7.3.1. Analysis by Trial Registration Year
  • 7.3.2. Analysis by Trial Phase
  • 7.3.3. Analysis by Trial Recruitment Status
  • 7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
  • 7.3.5. Analysis by Study Design
  • 7.3.6. Analysis by Sponsor / Collaborator
  • 7.3.7. Leading Players: Analysis by Number of Registered Trials
  • 7.3.8. Word Cloud: Key Focus Areas
  • 7.3.9. Analysis by Target Immune Checkpoint
  • 7.3.10. Analysis by Target Therapeutic Area
  • 7.3.11. Popular Indications: Analysis by Number of Registered Trials
  • 7.3.12. Popular Interventions: Analysis by Number of Registered Trials
  • 7.3.13. Geographical Analysis by Number of Registered Trials
  • 7.3.14. Geographical Analysis by Number of Patients Enrolled

8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS

• 8.1. Chapter Overview
• 8.2. Bristol-Myers Squibb
  • 8.2.1. Company Overview
  • 8.2.2. Financial Information
  • 8.2.3. Next Generation Immune Checkpoint Therapeutics Portfolio
  • 8.2.4. Recent Developments and Future Outlook
• 8.3. GlaxoSmithKline
  • 8.3.1. Company Overview
  • 8.3.2. Financial Information
  • 8.3.3. Next Generation Immune Checkpoint Therapeutics Portfolio
  • 8.3.4. Recent Developments and Future Outlook
• 8.4. Incyte
  • 8.4.1. Company Overview
  • 8.4.2. Financial Information
  • 8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
  • 8.4.4. Recent Developments and Future Outlook
• 8.4. Novartis
  • 8.4.1. Company Overview
  • 8.4.2. Financial Information
  • 8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
  • 8.4.4. Recent Developments and Future Outlook
• 8.5. Trillium Therapeutics
  • 8.5.1. Company Overview
  • 8.5.2. Financial Information
  • 8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio
  • 8.5.4. Recent Developments and Future Outlook

9. ACADEMIC GRANTS ANALYSIS

• 9.1. Chapter Overview
• 9.2. Scope and Methodology
• 9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
  • 9.3.1. Analysis by Year of Grant Award
  • 9.3.2. Analysis by Amount Awarded
  • 9.3.3. Analysis by Administering Institute Center
  • 9.3.4. Analysis by Funding Institute Center
  • 9.3.5. Analysis by Support Period
  • 9.3.6. Analysis by Funding Institute Center and Support Period
  • 9.3.7. Analysis by Type of Grant Application
  • 9.3.8. Analysis by Purpose of Grant Award
  • 9.3.9. Analysis by Grant Mechanism
  • 9.3.10. Word Cloud: Emerging Focus Areas
  • 9.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants
  • 9.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints
  • 9.3.13. Analysis by Study Section Involved
  • 9.3.14. Popular NIH Departments: Analysis by Number of Grants
  • 9.3.15. Analysis by Types of Recipient Organizations
  • 9.3.16. Popular Recipient Organizations: Analysis by Number of Grants
  • 9.3.17. Prominent Program Officers: Analysis by Number of Grants
  • 9.3.18. Regional Analysis of Recipient Organizations

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Partnership
  • 10.3.2. Analysis by Type of Partnership
  • 10.3.3. Analysis by Number of Partnership and Target Immune Checkpoint
  • 10.3.4. Analysis by Year of Partnership and Type of Partner
  • 10.3.5. Analysis by Type of Partnership and Type of Partner
  • 10.3.6. Most Active Players: Analysis by Number of Partnerships
• 10.4. Regional Analysis
  • 10.4.1. Intercontinental and Intracontinental Agreements

11. TARGET COMPETITIVENESS ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Key Parameters
• 11.4. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators
  • 11.3.1. Four-Dimensional Bubble Analysis
  • 11.3.2 Five-Dimensional Spider Web Analysis

12. BIG PHARMA INITIATIVES

• 12.1. Chapter Overview
• 12.2. Big Pharma Initiatives Focused on Next Generation Immune Checkpoint
  • 12.2.1. Analysis by Number of Initiatives
  • 12.2.2. Analysis by Number of Targets
  • 12.2.3. Analysis by Product Development Strategy
  • 12.2.4. Analysis by Target Immune Checkpoint
  • 12.2.5. Grid Representation: Analysis by Product Development Strategy and Target Immune Checkpoint
  • 12.2.6. Analysis by Type of Intervention
• 12.3. Analysis by Target Disease Indication(s)
  • 12.3.1. Heat Map: Big Pharma Initiatives Focused on Oncological Indications
  • 12.3.2. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 13.1. Chapter Overview
• 13.2. Forecast Methodology and Key Assumptions
• 13.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, Till 2030
• 13.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Individual Product Sales Forecasts
  • 13.4.1. DARZALEX(R) (Janssen Pharmaceuticals)
    • 13.4.1.1. Target Patient Population
    • 13.4.1.2. Sales Forecast
  • 13.4.2. SAR650984 (Sanofi)
    • 13.4.2.1. Target Patient Population
    • 13.4.2.2. Sales Forecast
  • 13.4.3. RRx-001 (EpicentRx)
    • 13.4.3.1. Target Patient Population
    • 13.4.3.2. Sales Forecast
  • 13.4.4. GSK3359609 (GlaxoSmithKline)
    • 13.4.4.1. Target Patient Population
    • 13.4.4.2. Sales Forecast
  • 13.4.5. Omburtamab (Y-mAbs Therapeutics)
    • 13.4.5.1. Target Patient Population
    • 13.4.5.2. Sales Forecast
  • 13.6.7. APXOO5M (Apogenix)
    • 13.6.7.1. Target Patient Population
    • 13.6.7.2. Sales Forecast
  • 13.7.8. BI 655064 (Boehringer Ingelheim)
  • 13.7.1. Target Patient Population
    • 13.4.7.2. Sales Forecast
  • 13.4.8. BMS-986015 (Bristol-Myers Squibb)
    • 13.4.8.1. Target Patient Population
    • 13.4.8.2. Sales Forecast
  • 13.4.9. CFZ533 (Novartis)
    • 13.4.9.1. Target Patient Population
    • 13.4.9.2. Sales Forecast
  • 13.4.10. GBR 830 (Glenmark)
    • 13.4.10.1. Target Patient Population
    • 13.4.10.2. Sales Forecast
  • 13.4.11. KHK4083 (Kyowa Kirin)
    • 13.4.11.1. Target Patient Population
    • 13.4.11.2. Sales Forecast
  • 13.12.13. LAG525 (Novartis)
    • 13.12.13.1. Target Patient Population
    • 13.12.13.2. Sales Forecast
• 13.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region
  • 13.5.1. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in US, Till 2030
  • 13.5.2. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, Till 2030
  • 13.5.3. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, Till 2030
  • 13.5.4. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, Till 2030
  • 13.5.5. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy Till 2030
  • 13.5.6. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, Till 2030
  • 13.5.7. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, Till 2030
  • 13.5.8. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, Till 2030
  • 13.5.9. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, Till 2030
• 13.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area
  • 13.6.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Indications, Till 2030
  • 13.6.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-oncological Indications, Till 2030
• 13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication
  • 13.7.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, Till 2030
  • 13.7.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, Till 2030
  • 13.7.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, Till 2030
  • 13.7.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, Till 2030
  • 13.7.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, Till 2030
  • 13.7.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, Till 2030
  • 13.7.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, Till 2030
  • 13.7.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, Till 2030
  • 13.7.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, Till 2030
  • 13.7.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, Till 2030
  • 13.7.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren's Syndrome, Till 2030
  • 13.7.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative Colitis, Till 2030
• 13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint
  • 13.8.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, Till 2030
  • 13.8.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, Till 2030
  • 13.8.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, Till 2030
  • 13.8.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, Till 2030
  • 13.8.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, Till 2030
  • 13.8.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, Till 2030
  • 13.8.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, Till 2030
  • 13.8.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, Till 2030
• 13.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action
  • 13.9.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, Till 2030
  • 13.9.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, Till 2030
• 13.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality
  • 13.10.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, Till 2030
  • 13.10.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecules, Till 2030
• 13.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy
  • 13.11.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, Till 2030
  • 13.11.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, Till 2030
  • 13.11.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, Till 2030
• 13.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration
  • 13.12.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, Till 2030
  • 13.12.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, Till 2030
  • 13.12.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, Till 2030

14. CONCLUDING REMARKS

• 14.1. Chapter Overview
• 14.2. Key Takeaways

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS